ATE209645T1 - Neue verbindung, verfahren zu ihrer herstellung und antitumormittel - Google Patents

Neue verbindung, verfahren zu ihrer herstellung und antitumormittel

Info

Publication number
ATE209645T1
ATE209645T1 AT95920265T AT95920265T ATE209645T1 AT E209645 T1 ATE209645 T1 AT E209645T1 AT 95920265 T AT95920265 T AT 95920265T AT 95920265 T AT95920265 T AT 95920265T AT E209645 T1 ATE209645 T1 AT E209645T1
Authority
AT
Austria
Prior art keywords
hydrogen atom
group
lower alkyl
production
alkyl group
Prior art date
Application number
AT95920265T
Other languages
German (de)
English (en)
Inventor
Kyoji Tomita
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Yasunori Tsuzuki
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Application granted granted Critical
Publication of ATE209645T1 publication Critical patent/ATE209645T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95920265T 1994-06-14 1995-06-06 Neue verbindung, verfahren zu ihrer herstellung und antitumormittel ATE209645T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (fr) 1994-06-14 1995-06-06 Nouveau compose, son procede de production et agent antitumoral

Publications (1)

Publication Number Publication Date
ATE209645T1 true ATE209645T1 (de) 2001-12-15

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920265T ATE209645T1 (de) 1994-06-14 1995-06-06 Neue verbindung, verfahren zu ihrer herstellung und antitumormittel

Country Status (26)

Country Link
US (1) US5817669A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0787726B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3391796B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100350921B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1053668C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE209645T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679859B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9508037A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2192824C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ292631B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69524251T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0787726T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2163512T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI112485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU220072B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9606331A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO307255B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ287139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL181867B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT787726E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO117793B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2151770C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0787726T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK281341B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW319769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995034559A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL369531A1 (en) * 2001-09-26 2005-05-02 Bayer Pharmaceuticals Corporation 1,8-naphthyridine derivatives as antidiabetics
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
EP1610795A4 (en) * 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES
ES2424676T3 (es) * 2003-09-10 2013-10-07 Kyorin Pharmaceutical Co., Ltd. Derivado de ácido 7-(3-ciclopropilaminometil-1-pirrolidinil 4-sustituido)quinoloncarboxílico
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
CA2954578A1 (en) * 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 in treating cancer
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
RU2405781C2 (ru) * 2004-10-14 2010-12-10 Ф.Хоффманн-Ля Рош Аг 1, 5-нафтиридиназолидиноны, обладающие cdk1 антипролиферативной активностью
CA2583311A1 (en) * 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag Quinazolinylmethylenethiazolinones as cdk1 inhibitors
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
JP2009504192A (ja) * 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームDNA(rDNA)およびリボソームRNA(rRNA)核酸ならびにそれらの使用
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
KR20170118936A (ko) * 2005-09-02 2017-10-25 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한 (+)-1,4-디히드로-7-[(3s,4s)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
BRPI0615838A2 (pt) * 2005-09-14 2011-05-31 Janssen Pharmaceutica Nv 5-oxo-5,8-dihidro-pirido-pirimidinas como inibidores de ofc-fms cinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
BRPI0713637A2 (pt) * 2006-06-12 2012-10-23 Sunesis Pharmaceuticals Inc composição, composto, e , método para o tratamento de cáncer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
MX344865B (es) * 2006-08-02 2016-12-19 Sunesis Pharmaceuticals Inc Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
CA2703044C (en) * 2007-10-22 2016-05-10 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
AU2008335772B2 (en) * 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
BRPI0923780A2 (pt) * 2008-12-31 2015-07-21 Sunesis Pharmaceuticals Inc Processo para preparar composto, processo para decomposição do composto, composto, composição, método para tratar câncer, e, pelo menos um quilograma de composto
SG173855A1 (en) 2009-02-27 2011-09-29 Sunesis Pharmaceuticals Inc Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2712358B1 (en) 2011-05-13 2016-12-21 Array Biopharma, Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
WO2018174266A1 (ja) 2017-03-24 2018-09-27 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
GR861530B (en) * 1985-06-13 1986-12-31 Schering Corp Preparation process for polycyclic quinoline of naphthyridine and pyrazinopyridine
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd 1,4−ジヒドロ−4−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
HU220072B (hu) 2001-10-28
WO1995034559A1 (fr) 1995-12-21
KR100350921B1 (ko) 2002-11-18
FI965020A7 (fi) 1996-12-16
AU679859B2 (en) 1997-07-10
EP0787726B1 (en) 2001-11-28
PT787726E (pt) 2002-04-29
SI0787726T1 (en) 2002-04-30
BR9508037A (pt) 1997-09-16
JP3391796B2 (ja) 2003-03-31
EP0787726A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-08-06
NO965305L (no) 1997-02-04
MX9606331A (es) 1997-03-29
ES2163512T3 (es) 2002-02-01
DK0787726T3 (da) 2002-02-11
AU2576795A (en) 1996-01-05
EP0787726A1 (en) 1997-08-06
DE69524251D1 (de) 2002-01-10
HK1000495A1 (en) 2002-07-19
HU9603455D0 (en) 1997-02-28
NZ287139A (en) 1997-07-27
NO965305D0 (no) 1996-12-11
RU2151770C1 (ru) 2000-06-27
FI965020A0 (fi) 1996-12-13
CA2192824A1 (en) 1995-12-21
DE69524251T2 (de) 2002-07-11
CZ292631B6 (cs) 2003-11-12
CN1158614A (zh) 1997-09-03
RO117793B1 (ro) 2002-07-30
HUT75777A (en) 1997-05-28
PL317726A1 (en) 1997-04-28
SK157496A3 (en) 1997-08-06
CN1053668C (zh) 2000-06-21
CA2192824C (en) 2006-11-07
FI112485B (fi) 2003-12-15
SK281341B6 (sk) 2001-02-12
CZ364396A3 (en) 1997-06-11
TW319769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-11-11
PL181867B1 (pl) 2001-09-28
NO307255B1 (no) 2000-03-06
US5817669A (en) 1998-10-06

Similar Documents

Publication Publication Date Title
ATE209645T1 (de) Neue verbindung, verfahren zu ihrer herstellung und antitumormittel
ATE254612T1 (de) Zuckerderivate, geliermittel, geliermittelzubereitungen, verfahren zu ihrer herstellung und gelzubereitungen
ATE123494T1 (de) Chinolon-derivate und deren salze, verfahren zu deren herstellung und diese enthaltende antibakterielle wirkstoffe.
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
GR3033519T3 (en) Substituted pyridinesulfonamide compounds, herbicidal compositions containing them, and process for their production.
DE69311500D1 (de) 2,3-Diphenyl-5-pyrrolyl-furan Derivate, Verfahren und Zwischenprodukte für ihre Herstellung und ihre Verwendung als entzündungshemmende, antiallergische und blutplättchenaggregationshemmende Mittel
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
DE3174132D1 (en) New ethenylimidazole derivatives, processes for their preparation and pharmaceutical compositions containing them; intermediates, useful in their preparation and a process for the preparation thereof
AU1589695A (en) Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof
DE69204480D1 (de) Anilinderivate und Verfahren zu ihrer Herstellung.
DE3770913D1 (de) Cinnamylamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE139767T1 (de) Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte
DE68911095D1 (de) Antitumor-Substanz, Verfahren zu deren Herstellung und diese enthaltende Antikrebsmittel.
DK0627419T3 (da) Optisk aktive derivater af 1-phenylpyrrolidon og fremgangsmåde til fremstilling deraf
PT71432A (en) Clavulanic acid derivatives a process for their preparation and their use
DE69129605D1 (de) Verfahren zur Herstellung von N-Alkylpyrazolen
GR3001003T3 (en) Novel pregnane derivatives, processes for their preparaton and pharmaceutical compositions containing same
MY104164A (en) Heterocyclic compounds.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification